Literature DB >> 11187950

Aspirin for primary prevention. Treatment policy should be based on all trial evidence, not subgroup analysis.

L E Ramsay, P S Sanmuganathan, E J Wallis, P R Jackson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11187950      PMCID： PMC1119179     

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  8 in total

1.  Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. Hypertension Optimal Treatment.

Authors:  S E Kjeldsen; R E Kolloch; G Leonetti; J M Mallion; A Zanchetti; D Elmfeldt; I Warnold; L Hansson
Journal:  J Hypertens       Date:  2000-05       Impact factor: 4.844

2.  Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial.

Authors:  T W Meade; P J Brennan
Journal:  BMJ       Date:  2000-07-01

3.  British Hypertension Society guidelines for hypertension management 1999: summary.

Authors:  L E Ramsay; B Williams; G D Johnston; G A MacGregor; L Poston; J F Potter; N R Poulter; G Russell
Journal:  BMJ       Date:  1999-09-04

4.  Prospective study of aspirin use and risk of stroke in women.

Authors:  H Iso; C H Hennekens; M J Stampfer; K M Rexrode; G A Colditz; F E Speizer; W C Willett; J E Manson
Journal:  Stroke       Date:  1999-09       Impact factor: 7.914

5.  Final report on the aspirin component of the ongoing Physicians' Health Study.

Authors: 
Journal:  N Engl J Med       Date:  1989-07-20       Impact factor: 91.245

Review 6.  The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials.

Authors:  P J Roderick; H C Wilkes; T W Meade
Journal:  Br J Clin Pharmacol       Date:  1993-03       Impact factor: 4.335

7.  Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials.

Authors:  J He; P K Whelton; B Vu; M J Klag
Journal:  JAMA       Date:  1998-12-09       Impact factor: 56.272

8.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.

Authors:  L Hansson; A Zanchetti; S G Carruthers; B Dahlöf; D Elmfeldt; S Julius; J Ménard; K H Rahn; H Wedel; S Westerling
Journal:  Lancet       Date:  1998-06-13       Impact factor: 79.321
  8 in total
  2 in total

1.  Authors' reply on aspirin for primary prevention.

Authors:  T W Meade ; P J Brennan
Journal:  BMJ       Date:  2001-01-20

Review 2.  Aspirin for the prevention of cardiovascular events in the elderly.

Authors:  Isabelle Mahé; Alain Leizorovicz; Charles Caulin; Jean-François Bergmann
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.